aztreonam has been researched along with Liver Cirrhosis in 3 studies
Aztreonam: A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.
aztreonam : A synthetic monocyclic beta-lactam antibiotic (monobactam), used primarily to treat infections caused by Gram-negative bacteria. It inhibits mucopeptide synthesis in the bacterial cell wall, thereby blocking peptidoglycan crosslinking.
Liver Cirrhosis: Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aztreonam and cefotaxime were compared in 44 cirrhotic patients who had 52 episodes of gram-negative spontaneous peritonitis." | 9.07 | Aztreonam vs. cefotaxime in the treatment of gram-negative spontaneous peritonitis in cirrhotic patients. ( Alonso, T; Ariza, J; Esteve, M; Fernández Bañeres, F; Gudiol, F; Liñares, J; Xiol, X, 1991) |
| "The pharmacokinetics of aztreonam were studied in six healthy male subjects (group I) and 12 male patients with post-hepatitis liver cirrhosis and ascites." | 7.68 | Pharmacokinetics of aztreonam in patients with liver cirrhosis and ascites. ( Abdel Barry, M; el Guinaidy, M; el Touny, M; Osman, L; Sabbour, MS, 1992) |
| "Aztreonam and cefotaxime were compared in 44 cirrhotic patients who had 52 episodes of gram-negative spontaneous peritonitis." | 5.07 | Aztreonam vs. cefotaxime in the treatment of gram-negative spontaneous peritonitis in cirrhotic patients. ( Alonso, T; Ariza, J; Esteve, M; Fernández Bañeres, F; Gudiol, F; Liñares, J; Xiol, X, 1991) |
| "The pharmacokinetics of aztreonam were studied in six healthy male subjects (group I) and 12 male patients with post-hepatitis liver cirrhosis and ascites." | 3.68 | Pharmacokinetics of aztreonam in patients with liver cirrhosis and ascites. ( Abdel Barry, M; el Guinaidy, M; el Touny, M; Osman, L; Sabbour, MS, 1992) |
| "Aztreonam was administered as a single, 3-min, 1-g intravenous infusion to 18 subjects, including 6 with biopsy-proven, primary biliary cirrhosis, 6 with biopsy-proven, stable alcoholic cirrhosis, and 6 age- and sex-matched control subjects with normal hepatic functions." | 3.67 | Effects of cirrhosis on kinetics of aztreonam. ( Bartley, EA; Devlin, RG; Hudes, E; MacLeod, CM; Payne, JA; Vernam, K, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| MacLeod, CM | 1 |
| Bartley, EA | 1 |
| Payne, JA | 1 |
| Hudes, E | 1 |
| Vernam, K | 1 |
| Devlin, RG | 1 |
| el Touny, M | 1 |
| el Guinaidy, M | 1 |
| Abdel Barry, M | 1 |
| Osman, L | 1 |
| Sabbour, MS | 1 |
| Ariza, J | 1 |
| Xiol, X | 1 |
| Esteve, M | 1 |
| Fernández Bañeres, F | 1 |
| Liñares, J | 1 |
| Alonso, T | 1 |
| Gudiol, F | 1 |
1 trial available for aztreonam and Liver Cirrhosis
| Article | Year |
|---|---|
Aztreonam vs. cefotaxime in the treatment of gram-negative spontaneous peritonitis in cirrhotic patients.
Topics: Adult; Aged; Ascitic Fluid; Aztreonam; Bacterial Infections; Cefotaxime; Female; Gram-Negative Bacte | 1991 |
2 other studies available for aztreonam and Liver Cirrhosis
| Article | Year |
|---|---|
Effects of cirrhosis on kinetics of aztreonam.
Topics: Anti-Bacterial Agents; Aztreonam; Chromatography, High Pressure Liquid; Humans; Kinetics; Liver Cirr | 1984 |
Pharmacokinetics of aztreonam in patients with liver cirrhosis and ascites.
Topics: Adult; Ascites; Ascitic Fluid; Aztreonam; Humans; Injections, Intravenous; Liver Cirrhosis; Male | 1992 |